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ABSTRACT
Expression of Transcribed Ultraconserved Regions (T-UCRs) is often deregulated 
in cancer. The present study assesses the expression and methylation of three 
T-UCRs (Uc160, Uc283 and Uc346) in colorectal cancer (CRC) and explores the 
potential of T-UCR methylation in circulating DNA for the detection of adenomas and 
adenocarcinomas.
Expression levels of Uc160, Uc283 and Uc346 were lower in neoplastic tissues 
from 64 CRC patients (statistically significant for Uc160, p<0.001), compared to non-
malignant tissues, while methylation levels displayed the inverse pattern (p<0.001, 
p=0.001 and p=0.004 respectively). In colon cancer cell lines, overexpression of 
Uc160 and Uc346 led to increased proliferation and migration rates. Methylation 
levels of Uc160 in plasma of 50 CRC, 59 adenoma patients, 40 healthy subjects and 
12 patients with colon inflammation or diverticulosis predicted the presence of CRC 
with 35% sensitivity and 89% specificity (p=0.016), while methylation levels of the 
combination of all three T-UCRs resulted in 45% sensitivity and 74.3% specificity 
(p=0.013). In conclusion, studied T-UCRs’ expression and methylation status are 
deregulated in CRC while Uc160 and Uc346 appear to have a complicated role in CRC 
progression. Moreover their methylation status appears a promising non-invasive 
screening test for CRC, provided that the sensitivity of the assay is improved.
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INTRODUCTION
Colorectal cancer (CRC) is the second leading cause 
of cancer-related deaths for men and third for women 
worldwide, with 50,260 cases estimated for 2017 in 
United States [1]. A long-term decline in CRC incidence 
rates has been noted since the mid-1980s, which has been 
attributed mostly to early screening through colonoscopy 
and removal of precancerous lesions [2, 3]. However, 
screening is not routinely performed for persons younger 
than 50 years, resulting in increased incidence rates by 2% 
per year from 1993 through 2013 in this age group [1]. 
Furthermore, it has been established that early detection 
of malignant bowel lesions can significantly improve 
survival, but many CRCs are diagnosed at later stages, 
when the disease becomes symptomatic [4].
Screening for CRC through analysis of genetic or 
epigenetic markers in circulating cell-free DNA (ccfDNA), 
isolated from plasma or serum specimens, can provide a 
minimally invasive and low-cost method with higher 
probability of patient adherence compared to colonoscopy. 
CcfDNA originates from apoptotic and necrotic cells [5, 6] 
and is found at higher levels in cancer patients compared 
to healthy individuals [7, 8]. An increasing number of 
studies have investigated the role of ccfDNA as a cancer 
biomarker, identifying tumour-derived genetic and 
epigenetic characteristics in serum/plasma samples [9–
18]. Especially for CRC, identification of DNA mutations 
or methylated genetic regions, offers a clinically useful 
biomarker for CRC screening and monitoring response to 
therapy [15, 19–24].
Ultraconserved regions (UCRs) were first identified 
in 2004 as 481 segments longer than 200 bp, absolutely 
conserved between orthologous regions of the human, rat, 
and mouse genomes, that may have played an important 
role in shaping the landscape of gene regulation during 
mammalian evolution [25, 26]. Most UCRs are noncoding 
and are under negative selection that is much stronger 
than that in protein coding genes [27]. Specific groups 
of UCRs are differentially expressed or methylated in 
various tumor types and have been associated with disease 
outcome [28–40]. The majority of UCRs are transcribed 
(T-UCRs), while their transcription is in part regulated 
by methylation. In particular, Uc160, Uc283 and Uc346 
in CRC cells have been found to undergo specific CpG 
island hypermethylation-associated silencing compared 
with normal tissues, while DNA hypomethylation reversed 
this effect [40].
The aim of this study was to compare the expression 
and methylation levels of Uc160, Uc283 and Uc346 in 
colorectal adenocarcinomas, adenomas and non-malignant 
colonic tissues, explore their role in CRC progression and 
investigate the use of their methylation status in circulating 
DNA as a biomarker for CRC and colorectal adenomas.
RESULTS
Tissue T-UCR expression
Expression levels of Uc160, Uc283 and Uc346 were 
assessed in 51 adenocarcinomas and paired non-malignant 
tumor adjacent tissues. Additionally, Uc160 expression 
levels were assessed in 2 fresh frozen (FF) adenoma 
tissue specimens. Differences in expression levels were 
noted among adenocarcinomas and non-malignant tumor 
adjacent tissues. Non-malignant tissues demonstrated higher 
expression levels of Uc160, Uc283 and Uc346 compared to 
adenocarcinomas, although the difference was statistically 
significant only for Uc160 (p<0.001, p=0.182 and p=0.639 
respectively, Table 1, Figure 1). T-UCRs expression levels in 
adenocarcinomas were not associated with sex, age, tumor 
type (ulcerative or exophytic), location (left or right colon 
or rectum), stage, lymph node infiltration, differentiation 
and distant metastasis (Supplementary Table 1). Similarly, 
T-UCR levels were also independent of lifestyle factors i.e. 
alcohol, meat or coffee consumption, smoking and exercise. 
However, lower levels of tumor Uc346 (p=0.011, Figure 2) 
was noted in patients who at the time of surgery presented 
with adenocarcinomas and adenomas concomitantly.
Tissue T-UCR methylation
Methylation levels of Uc160, Uc283 and Uc346 
were assessed in 64 adenocarcinomas and paired, non-
Figure 1: Relative expression of Uc160 (A), Uc283 (B) and Uc346 (C) in adenocarcinomas and non-malignant tumor 
adjacent tissues.
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malignant, tumor-adjacent tissues, as well as in 6 FF 
adenomas. Methylation levels of Uc160, Uc283 and Uc346 
were significantly different among adenocarcinomas, non-
malignant tumor adjacent tissues and adenomas (p<0.001, 
p=0.001 and p=0.004 respectively, Table 2, Figure 3). 
Interestingly, the highest Uc160 methylation levels were 
noted in adenocarcinomas while Uc283 and Uc346 
methylation levels reached the highest values in adenomas. 
T-UCR methylation levels in adenocarcinomas were not 
correlated with expression levels in both adenocarcinomas 
and non-malignant tumor-adjacent tissues. Moreover, 
they were not associated with most clinicopathological 
characteristics (Supplementary Table 2) or lifestyle 
characteristics (Data not shown). However, methylation of 
Uc283 in adenocarcinomas was higher in patients without 
distant metastasis compared to patients with distant 
metastasis (p=0.021, Figure 4). Furthermore, a trend was 
noted for decreasing levels of Uc283 methylation in grade 
II compared to grade I tumors. Notably, grade I tumors 
exhibited almost double median value compared to grade 
II tumors (p=0.052).
Plasma T-UCR methylation
T-UCR methylation levels were assessed in plasma 
samples from 40 healthy participants, 12 participants with 
colon inflammation, 50 CRC patients and 59 adenoma 
patients. Plasma samples from 11 CRC patients and 1 
adenoma patient were collected postoperatively and 
were excluded from further analysis. Notably, β-actin 
plasma levels were higher in cancer patients compared 
to healthy controls, adenoma patients and inflammation 
Figure 2: Relative expression of Uc346 in adenocarcinomas and adenocarcinoma and adenoma coexistence.
Table 1: Relative expression of T-UCRs in adenocarcinomas, non-malignant tumor adjacent tissues and adenomas
Tissue Number of 
samples
Uc160 relative 
expression
P 
value
Uc283 relative 
expression
P 
value
Uc346 relative 
expression
P 
value
Non-malignant 
tumor adjacent
51 1.30 (0.14-4.50)
<0.001
0.94 (0-16.03)
0.182
0.21 (0-6.14)
0.639
Adenocarcinoma 51 0.56 (0.14-3.51) 0.52 (0-15.63) 0.20 (0-5.86)
Adenoma 2 0.36 (0.15-0.57) N/A N/A
Oncotarget21414www.oncotarget.com
Figure 3: Relative methylation of Uc160 (A), Uc283 (B) and Uc346 (C) in adenocarcinomas, non-malignant tumor adjacent 
tissues and adenomas.
Figure 4: Relative methylation of Uc283 in adenocarcinomas and association with distant metastasis.
Table 2: Relative methylation of T-UCRs in adenocarcinomas, non-malignant tumor adjacent tissues and adenomas
Tissue Number of 
samples
Uc160 relative 
methylation
P 
value
Uc283 relative 
methylation
P 
value
Uc346 relative 
methylation
P 
value
Non-malignant 
tumor adjacent
64 0.03 (0-6.22)
<0.001
0.13 (0-1.08)
0.001
0.002 (0-0.93)
0.004
Adenocarcinoma 64 0.59 (0-11.0) 0.27 (0-1.85) 0.005 (0-1.80)
Adenoma 6 0.55 (0.31-7.82) 0.46 (0.24-2.34) 0.11 (0-1.82)
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patients (p=0.042, median values 0.20, 0.12, 0.06 and 
0.04 respectively). Moreover, they were double in non-
smokers compared to smokers (p=0.046) but were not 
associated with other lifestyle factors (alcohol, meat and 
coffee consumption and exercise), patients’ BMI, tumor 
or adenoma size, adenoma location, grade of dysplasia 
or type. The plasma T-UCR methylation frequency 
was the highest in CRC patients and lowest in healthy 
controls (Table 3). Plasma Uc160 and Uc346 methylation 
levels differed significantly among the four groups of 
participants (p<0.001 and p=0.039 respectively). More 
specifically, cancer patients had the highest mean values 
respectively (0.08 and 0.04) compared to adenoma patients 
(0.02 and 0.02), inflammation patients (0.04 and 0) and 
healthy controls (0.005 and 0.001).
In cancer and adenoma patients, Uc160 plasma 
methylation levels were positively correlated with lesion size 
(tumor or adenoma) (p<0.001, Figure 5). Moreover they were 
considerably higher in patients with lymph node infiltration 
(p=0.024). In addition, the frequency of methylated Uc160 
in plasma was higher in male patients and in patients over 
60 years (p=0.023 and p=0.040) (Table 4). With regard to 
Uc346 plasma methylation levels, these were correlated 
with tissue methylation levels (p=0.011). For all T-UCRs, 
plasma methylation levels were not associated with the life 
style and clinicopathological parameters mentioned above. 
Combinations of the three methylated T-UCRs in plasma 
were investigated to identify one with the highest sensitivity 
and specificity for adenocarcinomas (Table 5 and Figure 
6A) and for adenocarcinomas or adenomas (Table 6 and 
Figure 6B). When taking into consideration both specificity 
and sensitivity, Uc160 and the sum of the three T-UCRs 
seem to be the most promising biomarkers for CRC, with 
sensitivity and specificity 35% and 89%, and 45% and 
74.3% respectively (p=0.016 and p=0.013). With regard to 
the detection of adenomas or adenocarcinomas, Uc160 and 
Uc346 had 30.2% sensitivity and 80.7% specificity although 
statistical significance was not achieved possibly due to the 
small number of patients (p=0.160).
It is worth mentioning that all CRC patients whose 
samples were collected postoperatively had negative 
plasma Uc160 methylation. Exceptions were two patients 
who had postoperative active disease and their Uc160 
levels remained positive: a stage D CRC patient (#062), 
who did not undergo metastasectomy, and an initially 
characterized as inflammation patient (#077), who was 
found to harbor liver metastasis from renal cancer. On 
the contrary, patient #134, who had a family history of 
CRC, maintained negative Uc160 plasma methylation 
status in three different time points (before undergoing 
colonoscopy, preoperatively and postoperatively). 
Further investigation into the association between the 
methylation status of these T-UCRs in plasma and family 
history of cancer revealed that a greater percentage of 
sporadic CRC patients presented with methylated Uc160 
(57.1%) and Uc346 (25%), compared to CRC patients 
with a first degree relative with any type of cancer 
(Uc160 15.4% and Uc346 7.7%) (p=0.052 and p=0.015, 
respectively). This difference in Uc160 methylation 
status remained the same when patients with adenomas 
(25% in general population vs 7.9% in patients with first 
degree relatives with cancer) were included in the CRC 
cohort (p=0.050). Additionally, the methylation levels 
of Uc160 were higher in sporadic CRC and adenoma 
patients (p= 0.049) compared to CRC patients with a first 
degree relative with cancer.
Cell proliferation
The role of Uc160 and Uc346, which appeared to 
be the most promising biomarkers, was further evaluated 
by overexpressing these two T-UCRs in HT-29, Caco-
2 and DLD-1 colon cancer cell lines. Cell proliferation 
rate was higher at 48h post transfection in all cell lines 
transfected with Uc160 and Uc346 compared to the 
control (Figure 7), reaching statistical significance for 
Uc160 in Caco-2 (p=0.008) and for Uc346 in DLD-1 
cells (p=0.033).
Table 3: Frequency of plasma T-UCR methylation in different groups of participants (preoperative samples only)
Methylation 
in Plasma
Methylation 
status
Category Total
Healthy controls Adenoma 
Patients
Ca Patients Other Patients
Uc160 Unmethylated 38 (95%) 52 (89.7%) 26 (66.7%) 9 (75%) 125
Methylated 2 (5%) 6 (10.3%) 13 (33.3%) 3 (25%) 24
Uc283 Unmethylated 38 (95%) 53 (91.4%) 34 (87.2%) 10 (83.3%) 135
Methylated 2 (5%) 5 (8.6%) 5 (12.8%) 2 (16.7%) 14
Uc346 Unmethylated 37 (92.5) 50 (86.2%) 30 (76.9%) 12 (100%) 129
Methylated 3 (7.5%) 8 (13.8%) 9 (23.1%) 0 (0%) 20
Total 40 58 39 12 149
Other patients: patients with inflammation or diverticulosis
Oncotarget21416www.oncotarget.com
Cell migration
In the scratch wound healing assay, colon cancer 
cells that transiently overexpressed Uc160 or Uc346 
displayed increased motility rates compared to the control 
at all time points and all cell lines (Figure 8). Although 
differences appeared small, the high reproducibility of the 
assay revealed that they were statistically significant. More 
specifically, Uc160 and Uc346 overexpressing HT-29 cells 
had increased motility rates at 24h compared to control cells 
(p=0.017 and p=0.041 respectively, Figure 8B and 8E), as 
well as DLD-1 cells (p=0.023 and p=0.004 respectively, 
Figure 8C and 8F). Differences in motility rates were also 
observed in Caco-2 cells at 24h, however without reaching 
statistical significance (p=0.260 and p=0.678 respectively, 
Figure 8A and 8D). Further analysis of DLD-1 cells with 
transwell migration assay confirmed the above results, 
with an increased number of Uc160 or Uc346 transfected 
cells migrating compared to control cells (p=0.005 for both 
T-UCRs overexpression) (Figure 9).
DISCUSSION
UCRs have been associated with development 
and progression of many cancer types including CRC 
through aberrations in expression levels, methylation 
and even single nucleotide frequencies [28–40]. For 
example, expression levels of Uc73 and Uc388 in CRC are 
significantly decreased in tumor tissues while Uc73 levels 
have been correlated with overall survival [31]. Moreover, 
a cancer specific Uc160, Uc283 and Uc346 methylation 
pattern has been identified in colon cancer cells while 
DNA demethylation reversed T-UCR silencing [40].
In the present study, expression and methylation 
levels of Uc160, Uc283 and Uc346 were assessed in 
colorectal adenocarcinomas, paired non-malignant tumor-
adjacent tissues and adenomas. Interestingly, we found 
that not only all CRC cases were methylated but also most 
normal tissues too. These findings provide a new insight 
on the presence of methylation in normal CRC tissue 
compared to previously reported findings whereby none 
of the normal colon tissues and only some of the colonic 
tumor tissue samples had methylated Uc160, Uc283 and 
Uc346 (72.29%, 65.85% and 46.91% respectively) [40]. 
This discrepancy in the results could be attributed possibly 
to differences in the sensitivity of the methodological 
approaches chosen (qMSP vs MSP) and the larger number 
of normal tissue samples used in our study (64 vs 5). 
Moreover, adenocarcinomas and adenomas exhibited 
higher levels compared to non-malignant tissues, in 
concordance with previous publications [40]. Surprisingly, 
methylation levels were highest in adenomas, probably 
due to the small number of adenoma tissue samples 
analyzed.
Figure 5: Correlation of plasma Uc160 methylation levels with adenocarcinoma or adenoma size.
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Figure 6: ROC curve analyses for plasma T-UCR methylation levels and colorectal adenocarcinomas (A) and colorectal 
adenocarcinomas or adenomas (B).
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Table 4: Characteristics of the patients with positive plasma Uc160 methylation
Patient 
code
Sex Age Category Tumor 
Differentiation
Lymph Node 
infiltration
Stage 
(Duke’s)
Tumor/ 
Adenoma Size
Tumor/Adenoma 
Position
045 M 64 Ad 0.5 Left colon
049 M 80 Ad 2.5 Rectum
053 F 59 CRC Intermediate Yes C 5.5 Right colon
062 F 67 CRC Intermediate Yes D 4.5 Left colon
064 F 49 H
066 M 72 CRC Low No A 2.8 Left Colon
077 M 40 In
079 F 86 CRC No B 5.5 Right colon
084 M 61 Ad 4 Right colon
090 M 73 Ad 0.6 Right colon
095 M 80 CRC Intermediate Yes D 5.8 Right colon
102 M 75 Div
104 M 63 Ad 0.15 Left colon
113 F 83 Ad 0.4 Left colon and 
rectum
130 M 63 In
131 M 77 CRC Intermediate No B 5.3 Rectum
138 M 82 CRC Yes C 8 Rectum
147 M 64 CRC Intermediate Yes C 3.3 Left colon
148 M 9 CRC Intermediate Yes C 2.5 Right colon
156 M 43 CRC Intermediate Yes D 5.5 Rectum
165 M 64 CRC Intermediate Yes C 6.5 Left colon
198 M 80 CRC Intermediate Yes C 5 Rectum
224 F 66 H
229 M 62 CRC Intermediate Yes D 5.5 Left colon
230 F 73 CRC Intermediate Yes D 5.5 Rectum
243 M 69 CRC Intermediate No B 5.8 Right colon
M: male, F: female, Ad: adenoma, H: healthy, In: inflammation, Div: diverticulosis
Table 5: Sensitivity and specificity values of plasma T-UCR methylation for colorectal adenocarcinoma
Plasma methylation levels Sensitivity Specificity AUC P value
Uc160 35% 89% 0.628 0.016
Uc283 12.5% 92.7% 0.529 0.591
Uc346 22.5% 77.5% 0.566 0.221
Uc160 + Uc283 40% 82.6% 0.627 0.018
Uc160 + Uc346 42.5% 80.7% 0.639 0.009
Uc283 + Uc346 30% 83.5% 0.577 0.151
Uc160 + Uc283 + Uc346 45% 74.3% 0.633 0.013
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Furthermore, patients without metastasis displayed 
increased levels of Uc283 CRC tissue methylation 
compared to patients with metastasis. To our knowledge 
previous publications have focused only at lymph 
node and not distant metastases and reported a positive 
correlation between methylation status and positive 
lymph nodes for a pool of cancer patients with lymphoma, 
leukemia, colon, breast and lung cancer [40].
Since T-UCRs are highly methylated in CRC 
tissues compared to normal colon, higher levels of 
T-UCR expression were anticipated for non-malignant 
colon samples compared to CRC tissues. This was indeed 
observed for Uc160 and Uc283 (although not statistically 
significant for Uc283) but not for Uc346. This discrepancy 
may originate partly from the complex transcriptional 
regulation of T-UCRs that involves miRNA binding. 
Notably, Uc160 and Uc346 have been reported to have 
significant antisense complementarity to miRNAs, giving 
rise to six possible interacting pairs [28].
Another interesting observation was that b-actin 
levels were higher in CRC patients compared to healthy 
controls, adenoma patients or inflammation patients, 
reflecting the presence of a higher concentration of 
ccfDNA in accordance with previous publications, [7, 8, 
41, 42]. Similarly, methylation levels of Uc160 and Uc346 
were higher in the plasma of CRC patients compared 
to adenoma patients, inflammation patients or healthy 
controls as expected from the differences in methylation 
levels noted in the tissues. In addition, plasma Uc160 
methylation levels were positively correlated with lymph 
node infiltration and lesion size (tumor or adenoma), 
possibly due to the higher levels of tumor DNA being 
released from the neoplastic lesion, which increases the 
detection sensitivity of ccfDNA, as has been observed for 
other molecules [43].
Along the same line, it is of great interest that none of 
the patients whose samples were collected postoperatively 
was positive for plasma Uc160 methylation, with the 
exception of a stage D patient without metastasectomy, 
reflecting active disease. Supportive to this observation 
is the case of a stage C patient who had positive plasma 
Uc160 methylation preoperatively and which turned to 
negative after the surgical removal of the tumor and the 
infiltrated lymph nodes. In accordance with our results, 
postoperative detection of other methylated markers such 
as serum TFPI2 have been associated with R2 surgery, 
where active disease is present [44].
Of special interest is the negative plasma Uc160 
methylation status observed in all 3 samples collected 
at different time points, preoperatively (from 2 different 
Table 6: Sensitivity and specificity values of plasma T-UCR methylation for colorectal adenoma or adenocarcinoma
Plasma methylation levels Sensitivity Specificity AUC P value
Uc160 20.8 88.7% 0.554 0.276
Uc283 9.4% 92.5% 0.511 0.826
Uc346 17.1% 94.3% 0.562 0.210
Uc160 + Uc283 26% 81.1% 0.557 0.252
Uc160 + Uc346 30.2% 83% 0.570 0.160
Uc283 + Uc346 24% 86.8% 0.548 0.332
Uc160 + Uc283 + Uc346 34.4% 75.5% 0.581 0.252
Figure 7: MTT proliferation assay for Caco-2 (A) HT-29 (B), and DLD-1 (C) transiently transfected cells with Uc160 and 
Uc346 expressed in percentage of control cells (mean ±SEM).
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Departments) and postoperatively for a patient with CRC 
family history. This not only reinforces the reliability of 
the methodology but also raises the question of whether 
the role of T-UCRs differs between sporadic and familial 
CRC, since there was also a negative correlation between 
the methylation status of Uc160 and Uc346 and a family 
history of cancer. Such differences have been observed 
before in miRNA methylation levels, where higher 
methylation levels were noted in sporadic CRC cases 
compared to Lynch syndrome patients [45].
Considering the aforementioned findings, we 
explored the possibility of whether the methylation 
status of these three T-UCRs in plasma could constitute 
a minimally invasive biomarker for CRC or adenomas. 
Uc160 and the sum of the three T-UCRs were identified 
as the most promising biomarkers, with sensitivity 
and specificity 35% and 89%, and 45% and 74.3% 
respectively. So far, plasma methylation of SEPT9 seems 
to have the highest sensitivity and specificity (reaching 
95.6% and 84.8% respectively) for CRC, although these 
Figure 8: Scratch wound healing assay in HT-29, Caco-2 and DLD-1 cells transiently transfected with Uc160 and 
Uc346.  Wound closure in Caco-2 (A), HT-29 (B) and DLD-1 (C) cells in 24h and 48h as expressed in percentage of the surface at 0h (mean 
±SEM). Representative images of Caco-2 (D), HT-29 (E) and DLD-1 (F) cells at 0h and 24h at a magnification of 5x.
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values drop to 9.6% for adenomas [46, 47]. Although 
these results led to the development of SEPT9 plasma 
methylation kits for clinical use, retrospective studies 
reported conflicting results, with the sensitivity of the kit 
dropping to as low as 50.9% [46–49].
With regard to plasma methylation biomarkers for 
adenoma detection, the majority of published reports state 
relatively low specificities [50, 51]. Nevertheless there 
is an earlier study on plasma methylation of RASSF2A, 
APC, MGMT and Wif-1 that suggested a more promising 
biomarker panel for adenoma with sensitivity of 86.5% 
and specificity of 92.1% [52]. It remains an interesting 
question whether this will be transferred to the clinic as a 
follow up study has not yet been published. In our study, 
inclusion of a larger cohort of adenoma patients could 
potentially uncover a similar role for Uc160 and Uc346 
plasma methylation.
Since Uc160 and Uc346 seem to have a good 
potential as biomarkers, we aimed to assess their 
significance in tumor progression. Overexpression of 
Uc160 or Uc346 in CRC cell lines resulted to an increase 
in the proliferation as well as in the migration rate of the 
cells, supporting an oncogenic role for these long non-
coding RNAs in the metastatic process of CRC, as it 
has been reported for other T-UCRs [53]. These findings 
are in line with the higher expression of Uc346 and 
lower methylation levels of Uc346 and Uc160 in CRC 
patients who tended to have distant metastasis more often 
compared to patients with lower Uc346 expression and 
higher methylation levels. It is of note that, although these 
T-UCRs are downregulated in CRC and CRC cell lines, 
overexpression led to increased proliferation and migration 
rate. Similar contrasting observations have been noted 
also for Uc73, whose upregulation associates with colon 
tumorigenesis [28]. On the contrary a positive correlation 
of Uc73 with overall survival was noted elsewhere, 
suggesting a potential role of Uc73 as a tumor suppressor 
in CRC [31]. These discrepancies further highlight the 
complicated role of T-UCRs in CRC evolution.
In conclusion, methylation and expression of 
Uc160, Uc283 and Uc346 are deregulated in CRC while 
Uc160 and Uc346 may participate in the metastatic 
process of CRC. Plasma methylation of Uc160, Uc283 
and Uc346 is a promising biomarker for both CRC and 
adenomas mainly due to the good specificity observed. 
However, improvements in the methodological 
approach are necessary to increase the sensitivity of 
this assay.
Figure 9: Migration of DLD-1 cells transiently transfected with Uc160 and Uc346 towards 10% FBS in comparison to 
control cells. Representative images of control (A), Uc160 (B) and Uc346 (C) at a magnification of 40x. Number of migrated cells per 
field (D) represented as mean ±SEM.
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Table 7: Demographic and life style characteristics of the participants
Demographic characteristics Cancer Patients Adenoma Patients Inflammation 
patients
Healthy individuals
Gender Male 33 (66%) 38 (64.4%) 6 (50%) 12 (30%)
Female 17 (34%) 21 (35.6%) 6 (50%) 28 (70%)
Age Group 60≥ 16 (32%) 20 (33.9%) 4 (33.3%) 24 (60%)
>60 34 (68%) 39 (66.1%) 8 (66.6%) 16 (40%)
Smoking No 16 (32%) 30 (50.8%) 6 (50%) 32 (80%)
Yes 9 (18%) 23 (39%) 5 (41.7%) 8 (20%)
Cancer Family 
History
No 7 (14%) 25 (42.4%) 5 (41.7%) 19 (47.5%)
Yes 13 (26%) 26 (44.1%) 6 (50%) 17 (42.5%)
Coffee 
consumption
No 7 (14%) 9 (15.3%) 1 (8.3%) 6 (15%)
Yes 13 (26%) 43 (72.9%) 10 (83.3%) 34 (85%)
Alcohol 
consumption
No 16 (32%) 26 (44.1%) 5 (41.7%) 22 (55%)
Yes 8 (16%) 29 (49.1%) 6 (50%) 18 (45%)
Meat 
consumption
<2 times/wk 6 (3%) 9 (15.3%) 2 (16.7%) 7 (17.5%)
>2 &<4/wk 3 (6%) 31 (52.5%) 3 (25%) 14 (35%)
>4/wk 11 (22%) 11 (18.6%) 5 (41.7%) 18 (45%)
Exercise Occasionally 13 (26%) 36 (61%) 7 (58.3%) 22 (55%)
Often 11 (22%) 18 (30.5%) 4 (33.3%) 18 (45%)
Figure 10: Workflow of the study.
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MATERIALS AND METHODS
The outline of the workflow of our study is shown 
in Figure 10.
Patients and samples
This study was approved by the local Research 
Ethics Committee of the University Hospital of Patras, 
Greece and informed consent was obtained from all 
participants. Sixty four patients with CRC, 59 patients with 
adenomas, 40 control subjects and 12 patients with colon 
inflammation were enrolled in the study at the University 
Hospital of Patras (Departments of Gastroenterology, 
Surgery and Medical Oncology) between November 
2012 and April 2014. Clinical diagnosis was determined 
on the basis of colonoscopic findings and histological 
assessment. Control subjects underwent colonoscopy as 
part of a screening routine. Sixty four tumor and paired 
non-malignant specimens were obtained from the CRC 
patients and 6 adenoma specimens were obtained from 
the adenomas-only patients. Specimens were stored in 
RNAlater RNA Stabilization Reagent (Sigma–Aldrich, 
Austria) at -80°C. Blood samples were collected by 
phlebotomy prior to colonoscopy (Department of 
Gastroenterology) or prior to surgical excision of the tumor 
(Department of Surgery) or postoperatively (Department 
of Oncology) in K2EDTA Vacuette tubes (Greiner BioOne, 
Germany). Plasma was prepared within 2 hours of blood 
collection by centrifugation at 3000 rpm for 20 minutes 
at 4°C and was stored at -80°C until testing. Participants’ 
characteristics are shown in Table 7.
RNA preparation and cDNA synthesis
Total RNA was extracted from 80 mg neoplastic 
and paired non-malignant tumor adjacent FF tissue 
specimens from 51 CRC patients, as well as from 2 FF 
adenoma tissue specimens using the PerfectPure RNA 
Tissue Kit (5Prime, Hamburg, Germany), according to 
the manufacturers’ instructions. RNA samples were then 
incubated with DNase (Ambion, Austin, TX, USA) and 
quantified using a Nanodrop-1000 spectrophotometer 
(NanoDrop, Fisher Thermo, Wilmington, DE, USA). 
RNA integrity was checked by electrophoresis on 1% 
(w/v) agarose gels and the RNA was stored at -80°C. A 
total of 3 μg of RNA was reverse transcribed into cDNA 
using 100 U of Superscript III Reverse Transcriptase (Life 
Technologies), 300 ng of random primers (Foundation 
for Research and Technology-Hellas, Crete, Greece) and 
5 nM dNTPs (Stratagene) in a total volume of 50 μl. A no 
enzyme control was used to ensure that the RNA samples 
were DNA-free. The mixture was incubated in a C1000 
Touch thermal cycler (Bio-Rad) at 25°C for 5 minutes, 
50°C for 60 minutes, and 70°C for 15 minutes. CDNA was 
diluted to 30 ng/μl and stored at -20°C.
Quantification of T-UCRs expression
Expression levels of T-UCRs 160, 283 and 346 
were quantified by pre-optimized real-time PCR (qPCR) 
assays (Primer-Design Ltd, Hants, UK) modified to allow 
the use of dual labeled hydrolysis probes (Supplementary 
Table 3). The qPCR reactions were carried out in 
triplicate in a total volume of 20 μl, containing 5μl of 
cDNA, 2×TaqMan Universal Master Mix II (Applied 
Biosystems, Foster City, CA) and 150 nM of the specific 
T-UCR primer mix. A no template control was used in all 
reactions. Cycling conditions were as follows: 95°C for 
10 minutes, 45 cycles at 95°C for 15 seconds and at 60°C 
for 1 minute. Expressed Alu-Sq repeats were used as a 
reference gene, as it was validated to be a stably expressed 
repeat sequence in normal and tumor tissues of different 
grades and stages [54, 55]. Primers for the Alu-Sq were 
synthesized by Metabion International AG (Martinsried, 
Germany) [56]. The relative expression levels of each 
T-UCR were calculated using the LinReg Program [57] 
and were normalized to the Alu-Sq levels.
DNA isolation and bisulfite conversion of tissue 
DNA
DNA was extracted from 25 mg neoplastic and 
paired non-malignant tumor adjacent FF tissue specimens 
from 64 CRC patients, as well as from 6 FF adenomas 
using the Nucleospin Tissue Kit (Macherey-Nagel, 
Düren, Germany) according to the manufacturer’s 
instructions. DNA was eluted in 30 μl elution buffer. A 
total of 1 μg DNA was bisulfite converted and recovered 
using the Qiagen Epitect DNA bisulfite kit (Qiagen, 
Hilden, Germany). Bisulfite converted DNA was eluted 
in 40 μl elution buffer diluted in a total volume of 200 μl 
and stored at -20°C.
DNA isolation and bisulfite conversion of 
ccfDNA
DNA was extracted from 4 ml plasma from 40 
healthy participants, 12 patients with colon inflammation, 
50 CRC patients and 59 adenoma patients using the 
QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 
DNA was eluted in 50μl elution buffer. Sodium bisulfite 
conversion of DNA was performed by the EZ DNA 
Methylation-Gold Kit (Zymo Research Corporation, 
Orange, CA) according to the manufacturer's protocol. 
Bisulfite converted DNA was eluted in 30μl elution buffer 
and stored at -20°C.
DNA methylation analysis of tissue and ccfDNA
The methylation status of T-UCRs 160, 283 and 346 
in tissue and ccfDNA samples was detected by real-time 
quantitative Methylation Specific PCR (qMSP). Bisulfite 
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treated-based methylation-specific primers and relevant 
Locked Nucleic Acid (LNA) dual labeled hydrolysis 
probes specific for methylated T-UCRs 160, 283 and 
346 were designed using MethPrimer [58], following the 
NCBI library sequences (http://www.ncbi.nlm.nih.gov/). 
UCbase 2.0 (http://ucbase.unimore.it/) was also used for the 
identification of possible SNPs in Uc160, Uc283 and Uc346 
promoter regions so that primers were designed outside 
regions with SNPs with known minor allele frequency of 
more than 0.01 [59] (Supplementary Table 4). Each primer 
and LNA probe was designed to bind to 2-3 CGs while 
assuring that no CGs were present in the region between the 
primers and the probe, so that the detected amplicons were 
fully methylated. Primers sequences were then subjected 
to BiSearch web-based primer analysis tool to ensure 
specificity of the bisulfite converted designed primers [60]. 
All primers and probes were synthesized by Metabion 
International AG (Martinsried, Germany) (sequences are 
shown in Supplementary Table 3). The qPCR reactions 
were carried out in triplicate, in a total volume of 20 μl, 
containing 5 μl of bisulfite converted DNA, 2× TaqMan 
Universal Master Mix II (Applied Biosystems, Foster City, 
CA), 300 nM of each primer and 75 nM of each probe. In 
all reactions three controls were used: a no template control, 
an unmethylated control (healthy donor blood DNA, 
bisulfite converted) and a fully methylated control (healthy 
donor blood DNA, in vitro methylated with SsI methylase, 
NEB Ipswich, MA and bisulfite converted). Serial dilutions 
of in vitro methylated DNA (100%, 10%, 1%, and 0.1%) 
were used to establish a standard curve. Methylation levels 
were finally normalized to β-actin levels, which was used 
as a reference gene, using previously reported primers and 
probe [61]. Cycling conditions were as follows: 95°C for 10 
minutes and 50 cycles at 95°C for 15 seconds and at 60°C 
for 1 minute (Supplementary Table 3).
When analyzing ccfDNA samples, a first round of 
PCR was also performed for each T-UCR, with external 
primers that bind to CpGs-free bisulfite converted DNA. 
The qPCR reactions were carried out in a total volume 
of 20 μl, containing 6 μl of bisulfite converted DNA, 5x 
Mg-free KAPA Taq HotStart Buffer (Kapa Biosystems, 
Woburn, MA, USA), 400nM of each primer, 800 nM 
dNTPs, 1.25 nM MgCl2 and 1.5 U KAPA Taq HotStart 
DNA Polymerase (KAPABIOSYSTEMS, Woburn, MA, 
USA). Cycling conditions were 95°C for 3 minutes, 15 
cycles at 95°C for 30 seconds, 56°C for 30 seconds and 
72°C for 1 minute (see Supplementary Table 3  for detailed 
annealing temperatures). All samples were considered 
positive if at least one of the three replicates demonstrated 
amplification and depending on the amplification 
efficiency if the Cycle threshold (Ct) value for methylated 
Uc160 and Uc283 was ≤40, for methylated Uc346 ≤42 
and for B-actin was ≤35.
Blind experimental design and analysis was 
performed with respect to the participants’ identities and 
data.
Statistical analysis
IBM SPSS Statistics for Windows, Version 21.0 
(Armonk, NY: IBMCorp) was used for all the analyses 
performed. Intergroup comparisons for the association 
of clinicopathological parameters with mRNA and 
methylation levels of Uc160, Uc283 and Uc346 were 
performed using Kruskal–Wallis and Mann–Whitney 
nonparametric tests. Comparisons between related groups 
were performed using Wilcoxon paired samples test for 
mRNA and methylation levels. Pearson correlation was 
used to detect potential correlations between T-UCRs 
methylation and mRNA levels, tumor size and methylation 
levels in plasma and tumors. Receiver Operating 
Characteristics (ROC) curve analysis and the area under 
the curve (AUC) were determined to define markers with 
highest sensitivity and specificity.
Cell culture
Caco-2, HT-29 and DLD-1 colon cancer cell 
lines were purchased from the American Type Culture 
Collection (ATCC). DLD-1 and HT-29 cells were cultured 
in RPMI 1640 medium with 10% fetal bovine serum 
(FBS) and Caco-2 cells were cultured in Eagle’s Minimum 
Essential medium (EMEM) with 10% FBS. Cells were 
cultured at 37°C, 5% CO2 and 100% humidity.
Cloning and transfection
Lujambio et al. [40] showed that Uc160 and Uc346 
are methylated in colon cancer cell lines. Therefore 
Uc160 and Uc346 were overexpressed in colon cancer 
cell lines and proliferation and migration were defined. 
Uc160 and Uc346 transcribed regions were amplified 
using two sets of primers for each T-UCR, one outer set 
and one inner set which included the restriction sites for 
XhoI and BamHI (Supplementary Table 5). PCR products 
as well as pcDNA3.1/Hygro(-) plasmid (Invitrogen) were 
digested with XhoI and BamHI, cleaned and ligated using 
DNA ligation kit (Takara). DH5a competent cells were 
transformed with the ligated products and plasmids were 
isolated from the cultures grown the selected colonies 
with Nucleospin Plasmid (Macherey – Nagel, Germany). 
Cell transfections were performed using TurboFect™ in 
vitro Transfection Reagent (Fermentas GmbH, Germany) 
for 20h according to the manufacturer's instructions. 
Transfection efficiency was confirmed before performing 
the proliferation and motility experiments (Supplementary 
Figure 1).
Cell proliferation
The effect of Uc160 and Uc346 overexpression 
on proliferation of cells was determined using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium-
bromide (MTT) assay. Briefly, Caco-2, HT-29 and DLD-
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1 cells were seeded at a density of 5 × 104 cells/well in 
24-well plates with full growth media and transiently 
transfected with 250 ng empty vector or plasmid with 
Uc160 or Uc346 for 20h. Cell proliferation was measured 
at 0h, 24h and 48h after transfection. MTT solution (5 mg/
mL in PBS) was added to each well (1/10 of the volume) 
and incubated for 4 h at 37°C. Medium was removed and 
formazan crystals were solubilized in 100 μL acidified 
isopropanol. The solution was transferred to 96-well 
plates and read in a microplate reader (Tecan, Sunrise, 
Magellan 2) at a wavelength of 570 nm using reference 
wavelength 620 nm. Cell numbers were calculated using 
standard curves that were generated for each cell line 
using an increasing number of cells plated per well. The 
experiments were performed three times in triplicate.
Scratch wound healing assay
Motility of Caco-2, HT-29 and DLD-1 cells was 
evaluated using the scratch wound healing assay. Briefly, 
cells were grown in 6-well plates in 90% confluency and 
transiently transfected with 1μg vector or plasmid with 
Uc160 or Uc346 for 20h. After transfection the cells were 
then wounded with a plastic pipette tip, rinsed with PBS 
and incubated with growth media. Images were captured 
at time 0h, 24h and 48h at a magnification of 5x using an 
Axiocam ERc 5s camera (Carl Zeiss Microscopy LLC) 
mounted on an inverted microscope (Axiovert 40 CFL, 
Carl Zeiss Microscopy LLC). The experiments were 
performed five times.
Transwell migration assay
Cell migration of DLD-1 was further evaluated 
using the transwell migration assay. Cells were transiently 
transfected with Uc160 or Uc346 or vector for 20h and left 
in full growth medium post-transfectionally for 24h. Cells 
were suspended in serum-free culture medium and 1×105 
cells were loaded onto the top of Transwell chambers 
equipped with 8.0 μm pore-size polycarbonate membranes 
(Corning Inc., NY, USA) and allowed to migrate towards 
10% FBS medium for 24h. Migrated cells were fixed with 
Carson’s buffer and stained with Giemsa. Images were 
captured at a magnification of 40x using an Axiocam 
ERc 5s camera (Carl Zeiss Microscopy LLC) mounted 
on an inverted microscope (Axiovert 40 CFL, Carl Zeiss 
Microscopy LLC) and the average number of migrated 
cells was calculated using five different fields.
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